Immunic, inc. to present preclinical data for vidofludimus calcium at the 17th congress of european crohn's and colitis organization and announces blinded baseline characteristics of its phase 2 caldose-1 trial of vidofludimus calcium in ulcerative colitis

New york, feb. 18, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that evelyn peelen, ph.d., senior manager translational pharmacology at immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (imu-838), the company's selective oral dhodh inhibitor, at the 17th congress of european crohn's and colitis organization (ecco).
IMUX Ratings Summary
IMUX Quant Ranking